US EditionEU panel backs Darzalex for high-risk smoldering multiple myeloma
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
EU panel backs Darzalex for high-risk smoldering multiple myeloma
A European Medicines Agency (EMA) committee recommended that Darzalex (daratumumab) given as an under-the-skin injection be approved for people with smoldering multiple myeloma (SMM) who are at high risk of developing overt multiple myeloma. SMM refers to an early, asymptomatic stage of multiple myeloma, characterized by abnormal plasma cells that have not yet caused symptoms but carry a risk of progressing to active disease. Standard care for S…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
